IP Verse

Medicinal Composition For Treating Cancer - EP3431105

The patent EP3431105 was granted to Osaka University on Jan 1, 2020. The application was originally filed on Mar 28, 2018 under application number EP18775737A. The patent is currently recorded with a legal status of "Revoked".

EP3431105

OSAKA UNIVERSITY
Application Number
EP18775737A
Filing Date
Mar 28, 2018
Status
Revoked
Jul 4, 2025
Grant Date
Jan 1, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GEVERS & ORESOct 1, 2020GEVERS PATENTSADMISSIBLE
J A KEMPOct 1, 2020J A KEMPADMISSIBLE
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBOct 1, 2020SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
GLAXOSMITHKLINESep 30, 2020KIMADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSESep 16, 2020KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO0231140
DESCRIPTIONWO2005035586
DESCRIPTIONWO9411523
INTERNATIONAL-SEARCH-REPORTWO2007044756
INTERNATIONAL-SEARCH-REPORTWO2013131010
INTERNATIONAL-SEARCH-REPORTWO2015179236
INTERNATIONAL-SEARCH-REPORTWO2017198631
OPPOSITIONJP2017065603
OPPOSITIONJP2017185935
OPPOSITIONUS10087259
OPPOSITIONUS2009214533
OPPOSITIONWO2007044756
OPPOSITIONWO2008073160
OPPOSITIONWO2013131010
OPPOSITIONWO2015063187
OPPOSITIONWO2015179236
OPPOSITIONWO2016092419
OPPOSITIONWO2017198631
OPPOSITIONWO2017205014
OPPOSITIONWO2018112032
OPPOSITIONWO2018181425
OTHEREP3616720
OTHERJP2017065603
OTHERJP2017185935
OTHERWO2007044756
OTHERWO2013131010
OTHERWO2016092419
OTHERWO2017198631
SEARCHWO2018112032

Non-Patent Literature (NPL) Citations (77) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- CURIGLIANO GIUSEPPE, "Immunity and autoimmunity: revising the concepts of response to breast cancer.", BREAST (EDINBURGH, SCOTLAND) OCT 2011, (201110), vol. 20 Suppl 3, ISSN 1532-3080, pages S71 - S74-
EXAMINATION- MATSUMOTO KOICHIRO ET AL, "B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, INC, US, (20040215), vol. 172, no. 4, ISSN 0022-1767, pages 2530 - 2541, XP002491039-
EXAMINATION- ROBERTSON FAITH C ET AL, "NKT cell networks in the regulation of tumor immunity.", FRONTIERS IN IMMUNOLOGY 2014, (2014), vol. 5, ISSN 1664-3224, page 543-
EXAMINATION- IRANI VASHTI ET AL, "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (20150418), vol. 67, no. 2, doi:10.1016/J.MOLIMM.2015.03.255, ISSN 0161-5890, pages 171 - 182, XP029246901
EXAMINATION- JERYL VILLADOLID, "Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Jeryl Villadolid1,", TRANSL LUNG CANCER RES, (20150101), vol. 4, no. 5, doi:10.3978/j.issn.2218-6751.2015.06.06, pages 560 - 575, XP055383844
OPPOSITION- Anonymous, "BV421 Mouse Anti-Human CCR8 (CD 198)", BD Biosciences, (20160000), pages 1 - 2, XP055769025-
OPPOSITION- Anonymous, "Immunoglobulin G", InvivoGen - Review, (20110000), URL: https://www.invivogen.com/sites/default/files/invivogen/resources/documents/reviews/review-ImmunoglobulinG-invivogen.pdf, XP055768630-
OPPOSITION- Anonymous, "Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors", clinicaltrials.gov, (20160310), pages 1 - 9, URL: https://clinicaltrials.gov/ct2/show/NCT02301130, XP002777941-
OPPOSITION- Anonymous, "Purified anti-mouse CD 198 (CCR8) Antibody", Biolegend Enabling Legendary Discovery, (20151216), pages 1 - 2, XP055769023-
OPPOSITION- Anonymous, "Purified anti-mouse CD198 (CCR8) antibody", Biolegend - Product sheet, (20151216), pages 1 - 2, URL: https://www.biolegend.com/en-us/products/purified-anti-mouse-cd198-ccr8-antibody-12025, XP055768629-
OPPOSITION- Anonymous, "Review InvivoGen: Immunoglobulin G", Invivogen Corp-Stephanie Trumtel, (20110000), page 1, XP055162751-
OPPOSITION- Anonymous, "Technical Manual: mFcgammaRIV ADCC Reporter Bioassay, Core Kit", Promega, (20170100), pages 1 - 20, XP055769013-
OPPOSITION- COGHILL et al., "CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease", Blood, (20130801), vol. 122, no. 5, pages 825 - 836, XP055768611-
OPPOSITION- DAS et al., "Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses", Journal of Experimental Medicine, (20130700), vol. 210, no. 8, pages 1509 - 1528, XP055768993-
OPPOSITION- DEBES G. F. et al., "CCL8 and skin T cells - an allergic 2011 attraction", Nat. Immunol, (20110200), vol. 12, no. 2, pages 111 - 112, XP055768623-
OPPOSITION- ONISHI, "Immunotherapy Approaches Targeting Regulatory T-Cells", Anticancer Res, (20120000), vol. 32, pages 997 - 1004, XP055559091-
OPPOSITION- "PE anti-mouse CD279(PD-1)ANTIBODY", BioLegend, (20160217), XP055739741-
OPPOSITION- SHIPMAN, LYDIA, "Tumour immunology: Interrogating intratumoral Treg cells", Nature Reviews Immunology, (20161205), XP055768926-
OPPOSITION- STALLARD, JIM, "New Approach Could Boost Immunotherapy for Breast Cancer", Memorial Sloan Kettering Cancer Center, (20161129), pages 1 - 5, URL: https://www. mskcc.org/news/new-approach-could-boost- im m u notherapy-for -breast -cancer, XP055768936-
OPPOSITION- Supporting evidence for date of VUB project information webpage-
OPPOSITION- T J Kipps, P Parham, J Punt, L A Herzenberg, "Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies.", The Journal of Experimental Medicine, (19850000), vol. 161, no. 1, pages 1 - 17, XP002609364-
OPPOSITION- VAN GINDERACHTER et al., "Blockade of the CCR8 chemokine receptor as novel cancer therapy", VUB Project information, (20170101), URL: https://cris.vub.be/en/projects/blockade-of-the-ccr8-chemokine-receptor-as-novel-cancer-therapy(0869ab0e-ebdf-4039-9236-5082675cdc15).html, XP055768612-
OPPOSITION- Yamamoto , K, Muro, H. Ishii, T, Kato, T. Tsushima, M. Takeoyama, S. Oizumi, T. Kawakami, T. Doi, "Developmental Therapeutics", ESMO, (20170900), page 28, XP055739768-
OPPOSITION- TAN et al., "Crystal clear: visualizing the 2016 intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies", Protein Cell, (20160000), vol. 7, no. 12, doi:10.1007/s13238-016-0337-7, pages 866 - 877, XP036124172
OPPOSITION- TAN et al., "Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies"", Protein & Cell, (20160000), vol. 7, no. 12, pages 866 - 877, XP036124172
OPPOSITION- TAN et al., "Crystal clear: visualizing the intervention mechanism of the PD- 1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies", Protein & Cell, (20161007), vol. 7, no. 12, doi:10.1007/s13238-016-0337-7, pages 866 - 877, XP036124172
OPPOSITION- DAY et al., "Preclinical mouse cancer models: a 2015 maze of opportunities and challenges", Cell, (20150000), vol. 163, doi:10.1016/j.cell.2015.08.068, pages 39 - 53, XP029280472
OPPOSITION- SPAIN et al., "Management of toxicities of 2016 immune checkpoint inhibitors", Canc. Treat. Rev., (20160000), vol. 44, doi:10.1016/j.ctrv.2016.02.001, pages 51 - 60, XP029434607
OPPOSITION- KLARENBEEK et al., "Targeting chemokines and chemokine receptors with antibodies", Drug Discovery Today: Technologies, (20121200), vol. 9, no. 4, doi:10.1016/j.ddtec.2012.05.003, pages e237 - e244, XP055435390
OPPOSITION- DEMPKE et al., "Second- and third-generation drugs for immuno-oncology treatment—The more the better?", European Journal of Cancer, (20170210), vol. 74, pages 55 - 72, XP029933747
OPPOSITION- DE SIMONE et al., "Transcriptional landscape of 2016 human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells", Immunity, (20160000), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, pages 1135 - 1147, XP029809250
OPPOSITION- DE SIMONE et al., "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.021, pages 1135 - 1147, XP029809250
OPPOSITION- De Simone Marco; Arrigoni Alberto; Rossetti Grazisa; Gruarin Paola; Ranzani Valeria; Politano Claudia; Bonnal Raoul J P; Provasi Elena; Sarnicola Maria Lucia; Panzeri Ilaria; Moro Monica; Crosti Mariacristina; Mazzara Saveria; Vaira Valentina; Bosari Silvano; Palleschi Alessandro; Santambrogio Luigi; Bovo Giorgio; Zucchini Nicola; Totis Mauro; Gianotti Luca; Cesana Giancarlo; Perego Roberto A; Maroni Nirvana; Pisani Ceretti Andrea; Opocher Enrico; De Francesco Raffaele; Geginat Jens; Stunnenberg Hendrik G; Abrignani Sergio; Pagani Massimiliano, "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, (20161115), vol. 45, pages 1135 - 1147, XP029809250
OPPOSITION- DE SIMONE, "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", Immunity, (20160000), vol. 45, pages 1135 - 1147, XP029809250
OPPOSITION- PLITAS et al., "Regulatory T cells exhibit distinct 2016 features in human breast cancer", Immunity, (20160000), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, pages 1122 - 1134, XP029809259
OPPOSITION- PLITAS et al., "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, (20160000), vol. 45, no. 5, pages 1122 - 1134, XP029809259
OPPOSITION- PLITAS et al., "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, (20161115), vol. 45, no. 5, doi:10.1016/j.immuni.2016.10.032, pages 1122 - 1134, XP029809259
OPPOSITION- Plitas George; Konopacki Catherine; Wu Kenmin; Bos Paula D; Morrow Monica; Putintseva Ekaterina V; Chudakov Dmitriy M; Rudensky Alexander Y, "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", Immunity, (20161115), vol. 45, pages 1122 - 1134, XP029809259
OPPOSITION- Frederick Arce Vargas; Andrew J S Furness; Isabelle Solomon; Kroopa Joshi; Leila Mekkaoui; Marta H Lesko; Enrique Miranda Rota; Rony Dahan; Andrew Georgiou; Anna Sledzinska; Assma Ben Aissa; Dafne Franz; Mariana Werner Sunderland; Yien Ning Sophia Wong; Jake Y Henry; Tim O’brien; David Nicol; Ben Challacombe; Stephen A Beers; Samra Turajlic; Martin Gore; James Larkin; Charles Swanton; Kerry A Chester; Martin Pule; Jeffrey V Ravetch; Teresa Marafioti; Karl S Peggs; Sergio A Quezada; Lavinia Spain; Andrew Wotherspoon; Nicholas Francis; Myles Smith; Dirk Strauss; Andrew Hayes; Aspasia Soultati; Mark Stares; Joanna Lynch; Nicos Fotiadis; Archana Fernando; Steve Hazell; Ashish Chandra; Lisa Pickering; Sarah Rudman; Simon Chowdhury; Mariam Jamal-Hanjani; Selvaraju Veeriah; Seema Shafi; Justyna Czyzewska-Khan; Diana Johnson; Joanne Laycock; Leticia Bosshard-Carter; Gerald Goh; Rachel Rosenthal; Pat Gorman; Nirupa Murugaesu; Robert E Hynds; Gareth Wilson; Nicolai J Birkbak; Tho, "Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors", Immunity, (20170418), vol. 46, no. 4, pages 577 - 586, XP055487134
OPPOSITION- IRANI et al., "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases", Molecular Immunology, (20150418), vol. 67, doi:10.1016/j.molimm.2015.03.255, pages 171 - 182, XP029246901
OPPOSITION- Su Shicheng, Liao Jianyou, Liu Jiang, Huang Di, He Chonghua, Chen Fei, Yang Linbing, Wu Wei, Chen Jianing, Lin Ling, Zeng Yunjie, Ouyang Nengtai, Cui Xiuying, Yao Herui, Su Fengxi, Huang Jian-Dong, Lieberman Judy, Liu Qiang, Song Erwei, "Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer", Cell Research, Springer Singapore, Singapore, Singapore , (20170401), vol. 27, no. 4, doi:10.1038/cr.2017.34, ISSN 1001-0602, pages 461 - 482, XP093008139
OPPOSITION- Yawei Liu, Ingrid Teige, Bryndis Birnir, Shohreh Issazadeh-Navikas, "Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE", Nature Medicine, Nature Pub. Co., (20060501), vol. 12, no. 5, doi:10.1038/nm1402, ISSN 10788956, pages 518 - 525, XP055191958
OPPOSITION- SHIPMAN et al., "Interrogating intratumoral Treg cells.", Nature Rev. Immunol., (20161205), vol. 17, pages 4 - 5, XP055739876
OPPOSITION- LARKIN et al., "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma", N. Engl. J. Med ., (20150000), vol. 373, pages 23 - 34, XP055316141
OPPOSITION- DIETZE et al., "Transient depletion of regulatory T 2011 cells in transgenic mice reactivates virus-specific CD 8+ T cells andreduces chronic retroviral set points", PNAS, (20110124), vol. 108, no. 6, pages 2420 - 2425, XP055768620
OPPOSITION- ISLAM et al., "Identification of human CCR8 as a 2013 CCL18 receptor", J. Exp. Med., (20130923), vol. 210, no. 10, pages 1889 - 1898, XP055768625
OPPOSITION- SIMPSON et al., "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma", J. Exp. Med., (20130000), vol. 210, no. 9, pages 1695 - 1710, XP009176006
OPPOSITION- BOS et al., "Transient regulatory T cell ablation 2013 deters oncogene -driven breast cancer and enhances radiotherapy", J. Exp. Med., (20131021), vol. 210, no. 11, pages 2435 - 2446, XP055768618
OPPOSITION- KIM J.M. et al., "Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure", Annals of Oncology, (20160520), vol. 27, no. 8, doi:10.1093/annonc/mdw217, pages 1492 - 1504, XP055390469
OPPOSITION- Yoshiko Takeuchi; Hiroyoshi Nishikawa, "Roles of regulatory T cells in cancer immunity", Int. Immunology, (20160509), vol. 28, no. 8, pages 401 - 409, XP055396222
OPPOSITION- K Mutalithas , C Guillen, C Raport, R Kolbeck, D Soler, C E Brightling, I D Pavord, A J Wardlaw, "Expression of CCR8 is increased in asthma", Clin Exp Allerg y, (20100800), vol. 40, no. 8, pages 1175 - 1185, XP055739771
OPPOSITION- KLAGES et al., "Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma", Cancer research, (20101000), vol. 70, no. 20, doi:10.1158/0008-5472.CAN-10-1736, pages 7788 - 7799, XP055045950
OPPOSITION- IIDA et al., "Nonfucosylated Therapeutic IgG1Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcgammaRIIIa", Clinical Cancer Research, (20060501), vol. 12, no. 9, doi:10.1158/1078-0432.CCR-05-2619, pages 2879 - 2887, XP002432763
OPPOSITION- ERUSLANOV et al., "Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas", Clin. Cancer Res., (20130000), vol. 19, no. 7, pages 1670 - 1680, XP055739724
OPPOSITION- Eruslanov; Taryn Staffs1; Wan-Ju Kim1; Irina Daurkin1; Scott M Gilbert1; Li-Ming Su1; Johannes Vieweg1; Yehia Daaka1 '2; And Sergei Kusmartsev, "Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas", Clinical Cancer Research, (20130130), vol. 19, no. 7, pages 1670 - 1680, XP055739724
OPPOSITION- Koji Kurose , Yoshihiro Ohue , Hisashi Wada , Shinsuke Iida , Takashi Ishida , Takashi Kojima , Toshihiko Doi , Susumu Suzuki, Midori Isobe , Takeru Funakoshi , Kazuhiro Kakimi , Hiroyoshi Nishikawa , Heiichiro Udono , Mikio Oka , Ryuzo Ueda 1, Eiichi Nakayama, "Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients", Clin. Cancer Research, (20151001), vol. 21, no. 19, pages 4327 - 4336, XP055739871
OPPOSITION- DEPIS et al., "Abstract 4532: Preclinical 2020 evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells", Cancer Res. Proceedings: AACR Annual Meeting, doi:0.1158/1538-744, (20200427), URL: https://cancerres.aacrjournals.org/content/80/16_Supplement/4532, XP055768627
OPPOSITION- PLITAS et al., "Abstract P 4-04 -11: Preferential 2016 expression of the chemokine receptor 8 (CCRB) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", Cancer Res., (20160000), vol. 76, no. Suppl. 4, XP055396219
OPPOSITION- PLITAS et al., "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target",", Cancer Res., (20160000), vol. 76, no. 4 Suppl., XP055396219
OPPOSITION- PLITAS et al., "Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX. Philadelphia (PA, (20151208), vol. 76, XP055396219
OPPOSITION- DANNULL et al., "Enhancement of vaccine- 2005 mediated antitumor immunity in cancer patients after depletion of regulatory T cells", J. Clin. Invest., (20050000), vol. 115, doi:10.1172/JCI25947, pages 3623 - 3633, XP002396935
OPPOSITION- ZELINSKYY et al., "The regulatory T- cell response 2009 during acute retroviral infection is locally defined and controls the magnitude and duration of the virus- specific cytotoxic T- cell", Blood, (20091008), vol. 114, no. 15, pages 3199 - 3207, XP055768621
OPPOSITION- BRUHNS, PIERRE, "Properties of mouse and human IgG receptors and their contribution to disease models", Blood, (20120425), vol. 119, no. 24, doi:10.1182/blood-2012-01-380121, pages 5640 - 5649, XP055249198
OPPOSITION- HOWARD et al., "LEC induces chemotaxis and 2000 adhesion by interacting with CCR1 and CCR8", Blood J, (20000801), vol. 96, no. 3, pages 840 - 845, XP055768624
OPPOSITION- Heiyoun Jung; Ashley Bischof; Karen Ebsworth; Linda Ertl; Thomas Schall; Israel Charo, "Combination therapy of chemokine receptor inhibition plus PDL- 1 blockade potentiates anti-tumor effects in a murine model of breast cancer", Journal of ImmunoTherapy of Cancer, (20151200), vol. 3, no. 2, page 227, XP021235255
OPPOSITION- FINOTELLO et al., "New strategies for 2017 cancer immunotherapy: targeting regulatory T cells", Genome Medicine, (20170000), vol. 9, doi:10.1186/s13073-017-0402-8, page 10, XP055396226
OPPOSITION- Harner Susanne, Noessner Elfriede, Nadas Korinna, Leumann-Runge Anke, Schiemann Matthias, Faber Fabienne L., Heinrich Joachim, Krauss-Etschmann Susanne, "Cord Blood Vα24-Vβ11+ Natural Killer T Cells Display a Th2-Chemokine Receptor Profile and Cytokine Responses", PLoS ONE, (20110131), vol. 6, no. 1, doi:10.1371/journal.pone.0015714, page e15714, XP093008173
OPPOSITION- RAJASEKARAN et al., "Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment", ImmunoTargets and Therapy, (20150515), vol. 4, doi:10.2147/ITT.S61292, pages 91 - 100, XP055382587
OPPOSITION- Berzofsky Jay, Terabe Masaki, "The Contrasting Roles of NKT Cells in Tumor Immunity", CURRENT MOLECULAR MEDICINE, BENTHAM SCIENCE PUBLISHERS, NL, NL , (20090801), vol. 9, no. 6, doi:10.2174/156652409788970706, ISSN 1566-5240, pages 667 - 672, XP093008177
OPPOSITION- VELA et al., "Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges", Frontiers in Immunology, (20150130), vol. 6, doi:10.3389/fimmu.2015.00012, pages 1 - 15, XP055455872
OPPOSITION- KIM et al., "Cutting edge: depletion of Foxp3p 2009 cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice", J. Immunol., (20091118), vol. 183, no. 22, pages 7631 - 7634, XP055768619
OPPOSITION- HOELZINGER et al., "Blockade of CCL1 inhibits T 2010 regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses", J. Immunol., (20100000), vol. 184, doi:10.4049/jimmunol.0904084, pages 6833 - 6842, XP055306968
OPPOSITION- HOELZINGER et al., "Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses", J. Immunol., (20100000), vol. 184, pages 6833 - 6842, XP055306968
OPPOSITION- HOELZINGER et al., "Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses", The Journal of Immunology, (20100507), vol. 184, no. 12, doi:10.4049/jimmunol.0904084, pages 6833 - 6842, XP055306968
SEARCH- TAN SHUGUANG ET AL, "Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies", PROTEIN & CELL, SPRINGER ASIA, BEIJING, CN, vol. 7, no. 12, doi:10.1007/S13238-016-0337-7, ISSN 1674-800X, (20161104), pages 866 - 877, (20161104), XP036124172 [Y] 6-20 * whole document, especially the Abstract; Table 1 *
SEARCH- PLITAS GEORGE ET AL, "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", IMMUNITY, CELL PRESS, US, (20161115), vol. 45, no. 5, doi:10.1016/J.IMMUNI.2016.10.032, ISSN 1074-7613, pages 1122 - 1134, XP029809259 [I] 1-5,11-20 * whole document, especially the Abstract * [Y] 6-20
SEARCH- G PLITAS ET AL, "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", CANCER RESEARCH, US, (20160215), vol. 76, no. 4 Supplement, doi:10.1158/1538-7445.SABCS15-P4-04-11, ISSN 0008-5472, pages P4-04-11 - P4-04-11, XP055396219 [I] 1-5,11-14 * whole document, especially the "Conclusions" * [Y] 6-20

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents